Quick Answer
ACRO BIOMEDICAL CO., LTD. reported Operating Income Loss of -$154.0 thousand for the year ending 2025.
- ACRO BIOMEDICAL CO., LTD. showed a decrease of -305.8% in Operating Income Loss from 2024 to 2025.
- This data is from ACRO BIOMEDICAL CO., LTD.'s annual report (Form 10-K), filed with the SEC on February 11, 2026.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2016: -$7.4 thousand | Q1 2017: -$22.4 thousand | Q2 2017: -$11.9 thousand | Q4 2017: $80.2 thousand | Q1 2018: $98.0 thousand | Q2 2018: $176.2 thousand | Q4 2018: -$94.2 thousand | Q1 2019: -$214.8 thousand | Q2 2019: -$68.1 thousand | Q3 2019: -$64.5 thousand | Q4 2019: -$75.4 thousand | Q1 2020: $81.6 thousand | Q2 2020: -$62.8 thousand | Q3 2020: -$71.5 thousand | Q1 2021: -$57.0 thousand | Q2 2021: -$793.3 thousand | Q3 2021: -$2.99 million | Q1 2022: -$3.93 million | Q2 2022: -$4.00 million | Q3 2022: -$4.01 million | Q1 2023: -$4.00 million | Q2 2023: -$3.19 million | Q3 2023: -$1.59 million | Q1 2024: -$10.3 thousand | Q2 2024: -$9.1 thousand | Q3 2024: -$9.1 thousand | Q1 2025: -$8.9 thousand | Q2 2025: -$13.6 thousand | Q3 2025: -$115.1 thousand.
- Over the full 10 years of available data (2017 to 2025), ACRO BIOMEDICAL CO., LTD.'s Operating Income Loss has declined by 6,751.6%.
- Historical annual values: Fiscal year 2025: -$154.0 thousand | Fiscal year 2024: -$38.0 thousand | Fiscal year 2023: -$8.80 million | Fiscal year 2022: -$15.87 million | Fiscal year 2021: -$7.69 million | Fiscal year 2020: -$130.5 thousand | Fiscal year 2019: -$422.8 thousand | Fiscal year 2019: -$441.6 thousand | Fiscal year 2018: $515.6 thousand | Fiscal year 2017: -$2.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: